Withdrawal of two generic clopidogrel products in Saudi Arabia for non-bio-equivalence

[1]  Wuqiang Fan,et al.  CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic , 2017, Journal of community hospital internal medicine perspectives.

[2]  S. Johnston,et al.  Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. , 2016, JAMA.

[3]  J. Szaflarski,et al.  Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial , 2016, The Lancet Neurology.

[4]  J. Le Heuzey,et al.  Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide , 2015, European Journal of Clinical Pharmacology.

[5]  Pravin P. Aute,et al.  Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada. , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[6]  R. Becker,et al.  Generic clopidogrel: time to substitute? , 2013, JAMA.

[7]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[8]  A. Ghaffar,et al.  Access to medicines from a health system perspective , 2012, Health policy and planning.

[9]  A. García‐Arieta,et al.  Bioequivalence Requirements in the European Union: Critical Discussion , 2012, The AAPS Journal.

[10]  W. Ageno,et al.  Brand Name versus Generic Warfarin: A Systematic Review of the Literature , 2011, Pharmacotherapy.

[11]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[12]  D. Hughes,et al.  Generic and therapeutic substitutions in the UK: are they a good thing? , 2010, British journal of clinical pharmacology.

[13]  A. Kesselheim,et al.  Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs , 2010, Drugs.

[14]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[15]  M Alan Brookhart,et al.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.

[16]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[17]  Peter Meredith,et al.  Bioequivalence and other unresolved issues in generic drug substitution. , 2003, Clinical therapeutics.

[18]  W. Belloso,et al.  [Cardiovascular pharmacogenomics]. , 2014, Archivos de cardiologia de Mexico.

[19]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .